BR112023002161A2 - Formas sólidas de dosagem de palbociclibe - Google Patents
Formas sólidas de dosagem de palbociclibeInfo
- Publication number
- BR112023002161A2 BR112023002161A2 BR112023002161A BR112023002161A BR112023002161A2 BR 112023002161 A2 BR112023002161 A2 BR 112023002161A2 BR 112023002161 A BR112023002161 A BR 112023002161A BR 112023002161 A BR112023002161 A BR 112023002161A BR 112023002161 A2 BR112023002161 A2 BR 112023002161A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage forms
- palbociclib
- solid dosage
- pharmaceutical compositions
- relates
- Prior art date
Links
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004390 palbociclib Drugs 0.000 title abstract 4
- 239000007909 solid dosage form Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
FORMAS SÓLIDAS DE DOSAGEM DE PALBOCICLIBE. A presente invenção refere-se a novas composições farmacêuticas compreendendo palbociclibe, como um composto farmaceuticamente ativo. Especificamente, a presente invenção refere-se a formas sólidas de dosagem de palbociclibe compreendendo pelo menos um composto selecionado a partir do grupo que consiste em aminoácido ou peptídeo contendo enxofre e pelo menos uma vitamina com propriedades antioxidantes. As formas de dosagem aqui descritas são preparações orais quimicamente estáveis possuindo características farmacocinéticas desejáveis e propriedades de dissolução. A invenção também é direcionada ao uso das referidas composições farmacêuticas como medicamento, em particular para o tratamento de câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033503 | 2020-08-05 | ||
| PCT/IN2021/050746 WO2022029799A1 (en) | 2020-08-05 | 2021-08-03 | Solid dosage forms of palbociclib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002161A2 true BR112023002161A2 (pt) | 2023-04-04 |
Family
ID=77821971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002161A BR112023002161A2 (pt) | 2020-08-05 | 2021-08-03 | Formas sólidas de dosagem de palbociclibe |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230263734A1 (pt) |
| EP (1) | EP4192439A1 (pt) |
| BR (1) | BR112023002161A2 (pt) |
| CA (1) | CA3190856A1 (pt) |
| CO (1) | CO2023002650A2 (pt) |
| MX (1) | MX2023001572A (pt) |
| WO (1) | WO2022029799A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4302755A1 (en) * | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing an amino acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35590A (es) * | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| WO2016156070A1 (en) * | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
-
2021
- 2021-08-03 CA CA3190856A patent/CA3190856A1/en active Pending
- 2021-08-03 MX MX2023001572A patent/MX2023001572A/es unknown
- 2021-08-03 US US18/019,582 patent/US20230263734A1/en active Pending
- 2021-08-03 EP EP21773160.3A patent/EP4192439A1/en active Pending
- 2021-08-03 WO PCT/IN2021/050746 patent/WO2022029799A1/en active Application Filing
- 2021-08-03 BR BR112023002161A patent/BR112023002161A2/pt unknown
-
2023
- 2023-03-02 CO CONC2023/0002650A patent/CO2023002650A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192439A1 (en) | 2023-06-14 |
| CO2023002650A2 (es) | 2023-06-20 |
| US20230263734A1 (en) | 2023-08-24 |
| CA3190856A1 (en) | 2022-02-10 |
| WO2022029799A1 (en) | 2022-02-10 |
| MX2023001572A (es) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
| BRPI0317463B8 (pt) | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina | |
| EA201070940A1 (ru) | Жидкая лекарственная форма фсг | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| BR112014021653A2 (pt) | Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
| BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
| BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
| BR112021018707A2 (pt) | Formulações compreendendo melflufeno | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| BR112023002161A2 (pt) | Formas sólidas de dosagem de palbociclibe | |
| EA201500506A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a | |
| BR112022020315A2 (pt) | Novos compostos anti-helmínticos | |
| BRPI0602397C1 (pt) | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições | |
| BR112021026292A2 (pt) | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria | |
| BR112017019753A2 (pt) | uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal | |
| BR112017022390A2 (pt) | composição farmacêutica | |
| BR112023026250A2 (pt) | Terapia de combinação tripla | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| CR20220620A (es) | Composición farmacéutica acuosa de levilimab y su uso |